Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?

Summary

Keros Therapeutics received a $20M milestone payment from Takeda Pharmaceutical, potentially unlocking significant commercial opportunities. The financial collaboration suggests progress on a therapeutic program between the two companies.